Research programme: metabolic disorder therapeutics - 7TM Pharma/Dr. Reddy's Laboratories
Latest Information Update: 06 Jul 2010
At a glance
- Originator 7TM Pharma; Dr Reddys Laboratories
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Metabolic disorders
Most Recent Events
- 06 Jul 2010 This programme is still in active development
- 17 Mar 2008 Early research in Metabolic disorders in USA (unspecified route)